Cargando…

Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review

Parkinson's disease (PD), a neurodegenerative disorder, is caused due to the loss of dopaminergic neurons in substantia nigra pars compacta, and it mainly affects the motor function of the diseased individual. The most effective treatment for PD to date is levodopa, the precursor molecule for d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaire, Suman, Kafle, Sunam, Bastakoti, Sanjiv, Paudel, Anuj, Karki, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514709/
https://www.ncbi.nlm.nih.gov/pubmed/34660137
http://dx.doi.org/10.7759/cureus.17949
_version_ 1784583452337635328
author Gaire, Suman
Kafle, Sunam
Bastakoti, Sanjiv
Paudel, Anuj
Karki, Kumar
author_facet Gaire, Suman
Kafle, Sunam
Bastakoti, Sanjiv
Paudel, Anuj
Karki, Kumar
author_sort Gaire, Suman
collection PubMed
description Parkinson's disease (PD), a neurodegenerative disorder, is caused due to the loss of dopaminergic neurons in substantia nigra pars compacta, and it mainly affects the motor function of the diseased individual. The most effective treatment for PD to date is levodopa, the precursor molecule for dopamine which ultimately helps overcome the loss of dopamine in the brain. However, long-term levodopa therapy significantly impairs patients' quality of life by causing various disabling motor and non-motor complications. We conducted this study intending to review the available literature that has compared the efficacy and safety of continuous subcutaneous apomorphine infusion (CSAI) with other available treatment options like deep brain stimulation, intestinal levodopa gel, and oral dopaminergic agents. We searched PubMed, Embase, and Scopus databases using the appropriate search strategy. The studies which compared the safety and efficacy of continuous subcutaneous apomorphine infusion to other available treatment options in advanced Parkinson’s disease were included in our study. The bias assessment of the studies was done using Cochrane Risk of Bias 2.0 tool for randomized controlled trials, Risk of Bias In Non-Randomized Studies - of Interventions (ROBINS-I) tool for non-randomized interventional studies, and Joanna Briggs Institute Critical Appraisal tools (JBI) for cohort studies. We included eight articles in our systematic review including a randomized controlled trial. None of the included studies had a high risk of bias. We found that in patients with advanced Parkinson’s, CSAI demonstrated definite improvement in off-time duration. CSAI has also been shown to improve various non-motor functions, including neuropsychiatric problems in these patients. CSAI has demonstrated safety and efficacy in patients with advanced Parkinson’s disease. However, the decision-making is multifactorial. Hence, further studies are required that directly compare the available treatment options with one another and study their overall effects on patients’ quality of life.
format Online
Article
Text
id pubmed-8514709
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-85147092021-10-15 Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review Gaire, Suman Kafle, Sunam Bastakoti, Sanjiv Paudel, Anuj Karki, Kumar Cureus Neurology Parkinson's disease (PD), a neurodegenerative disorder, is caused due to the loss of dopaminergic neurons in substantia nigra pars compacta, and it mainly affects the motor function of the diseased individual. The most effective treatment for PD to date is levodopa, the precursor molecule for dopamine which ultimately helps overcome the loss of dopamine in the brain. However, long-term levodopa therapy significantly impairs patients' quality of life by causing various disabling motor and non-motor complications. We conducted this study intending to review the available literature that has compared the efficacy and safety of continuous subcutaneous apomorphine infusion (CSAI) with other available treatment options like deep brain stimulation, intestinal levodopa gel, and oral dopaminergic agents. We searched PubMed, Embase, and Scopus databases using the appropriate search strategy. The studies which compared the safety and efficacy of continuous subcutaneous apomorphine infusion to other available treatment options in advanced Parkinson’s disease were included in our study. The bias assessment of the studies was done using Cochrane Risk of Bias 2.0 tool for randomized controlled trials, Risk of Bias In Non-Randomized Studies - of Interventions (ROBINS-I) tool for non-randomized interventional studies, and Joanna Briggs Institute Critical Appraisal tools (JBI) for cohort studies. We included eight articles in our systematic review including a randomized controlled trial. None of the included studies had a high risk of bias. We found that in patients with advanced Parkinson’s, CSAI demonstrated definite improvement in off-time duration. CSAI has also been shown to improve various non-motor functions, including neuropsychiatric problems in these patients. CSAI has demonstrated safety and efficacy in patients with advanced Parkinson’s disease. However, the decision-making is multifactorial. Hence, further studies are required that directly compare the available treatment options with one another and study their overall effects on patients’ quality of life. Cureus 2021-09-13 /pmc/articles/PMC8514709/ /pubmed/34660137 http://dx.doi.org/10.7759/cureus.17949 Text en Copyright © 2021, Gaire et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Neurology
Gaire, Suman
Kafle, Sunam
Bastakoti, Sanjiv
Paudel, Anuj
Karki, Kumar
Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title_full Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title_fullStr Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title_full_unstemmed Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title_short Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review
title_sort continuous subcutaneous apomorphine infusion in advanced parkinson’s disease: a systematic review
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514709/
https://www.ncbi.nlm.nih.gov/pubmed/34660137
http://dx.doi.org/10.7759/cureus.17949
work_keys_str_mv AT gairesuman continuoussubcutaneousapomorphineinfusioninadvancedparkinsonsdiseaseasystematicreview
AT kaflesunam continuoussubcutaneousapomorphineinfusioninadvancedparkinsonsdiseaseasystematicreview
AT bastakotisanjiv continuoussubcutaneousapomorphineinfusioninadvancedparkinsonsdiseaseasystematicreview
AT paudelanuj continuoussubcutaneousapomorphineinfusioninadvancedparkinsonsdiseaseasystematicreview
AT karkikumar continuoussubcutaneousapomorphineinfusioninadvancedparkinsonsdiseaseasystematicreview